Efficacy and Safety of Voriconazole (VORI) in the Treatment of Invasive Fungal Infection in Children.

T.J. WALSH, P. GHAHRAMANI, M.R. HODGES, I. LUTSAR

Abstract: 

Aim: To describe the efficacy and safety of VORI in children treated within the compassionate program. Methods: All children who received VORI on a compassionate basis due to failure and/or intolerance to previous antifungals prior to June 22, 1999, were analysed; patients [pts] with definite or probable invasive fungal infection were assessed for efficacy. VORI dosing: loading doses 6 mg/kg/q12h iv on Day 1, then 4 mg/kg/q12h iv onwards. If feasible iv VORI was switched to oral (100 mg/bid or 200 mg/bid for
2000

abstract No: 

NULL

Full conference title: 

Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 40th